JP2009132712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009132712A5 JP2009132712A5 JP2008298513A JP2008298513A JP2009132712A5 JP 2009132712 A5 JP2009132712 A5 JP 2009132712A5 JP 2008298513 A JP2008298513 A JP 2008298513A JP 2008298513 A JP2008298513 A JP 2008298513A JP 2009132712 A5 JP2009132712 A5 JP 2009132712A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- drug
- surfactant
- composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (11)
- 薬物の生物学的利用能を向上する経口投与用の医薬組成物であって、治療上有効量の親油性薬物、１つ以上の親水性担体、および１つ以上の界面活性剤を含み、前記組成物のＨＬＢ値は約８〜約１５の範囲にあるが、ただし、前記組成物は油相を含有しない経口投与用の医薬組成物。
- 前記薬物は、免疫薬、抗感染薬、抗高血圧薬、または血中脂質低下薬である、請求項１に記載の医薬組成物。
- 前記薬物は、シクロスポリン、タクロリムス、イブプロフェン、ケトプロフェン、ニフェジピン、アムロジピン、またはシンバスタチンである、請求項２に記載の医薬組成物。
- 前記親水性担体は、エタノール、イソプロパノール、ポリエチレングリコール（ＰＥＧ）、グリセリン、プロピレングリコール、およびそれらの混合物からなる群から選択される、請求項１に記載の医薬組成物。
- 前記界面活性剤は、カチオン性界面活性剤、アニオン性界面活性剤、非イオン性界面活性剤、およびそれらの混合物である、請求項１に記載の医薬組成物。
- 前記界面活性剤は、約２〜約１８の範囲のＨＬＢ値を有する、請求項５に記載の医薬組成物。
- 前記界面活性剤は、ＰＥＧ４０硬化ヒマシ油、ポリソルベート、コカミドプロピルベタイン、グリセリル・ココエート、ＰＥＧ６カプリル／カプリングリセリド、ポロキサマー、Ｌａｂｒａｆｉｌ Ｍ１９４４ＣＳ、Ｌａｂｒａｆｉｌ Ｍ２１２５ＣＳ、Ｌａｂｒａｓｏｌ、Ｃｒｅｍｏｐｈｏｒ ＥＬ、Ｃｒｅｍｏｐｈｏｒ ＲＨ、Ｂｒｉｊ、Ｓｐａｎおよびそれらの混合物からなる群から選択される、請求項６に記載の医薬組成物。
- 前記組成物は、水系溶液に接触すると、約８００ｎｍ未満の粒径のエマルジョン／マイクロエマルジョンを形成する、請求項１に記載の医薬組成物。
- 前記薬物は、前記組成物の約０．１重量％〜約５０重量％の量で存在する、請求項１に記載の医薬組成物。
- 前記親水性担体は、前記組成物の約１重量％〜約３０重量％の量で存在する、請求項１に記載の医薬組成物。
- 前記界面活性剤は、前記組成物の約１０重量％〜約９０重量％の量で存在する、請求項１に記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/944,239 | 2007-11-21 | ||
| US11/944,239 US20090130198A1 (en) | 2007-11-21 | 2007-11-21 | Pharmaceutical composition with enhanced bioavailability |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014038075A Division JP2014098039A (ja) | 2007-11-21 | 2014-02-28 | 生物学的利用能を向上した医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009132712A JP2009132712A (ja) | 2009-06-18 |
| JP2009132712A5 true JP2009132712A5 (ja) | 2011-11-10 |
| JP5491724B2 JP5491724B2 (ja) | 2014-05-14 |
Family
ID=40439733
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008298513A Active JP5491724B2 (ja) | 2007-11-21 | 2008-11-21 | 生物学的利用能を向上した医薬組成物 |
| JP2014038075A Pending JP2014098039A (ja) | 2007-11-21 | 2014-02-28 | 生物学的利用能を向上した医薬組成物 |
| JP2016053870A Pending JP2016106152A (ja) | 2007-11-21 | 2016-03-17 | 生物学的利用能を向上した医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014038075A Pending JP2014098039A (ja) | 2007-11-21 | 2014-02-28 | 生物学的利用能を向上した医薬組成物 |
| JP2016053870A Pending JP2016106152A (ja) | 2007-11-21 | 2016-03-17 | 生物学的利用能を向上した医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090130198A1 (ja) |
| EP (1) | EP2062571B8 (ja) |
| JP (3) | JP5491724B2 (ja) |
| CN (1) | CN101439015B (ja) |
| ES (1) | ES2396723T3 (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020354B1 (ru) * | 2008-12-03 | 2014-10-30 | Астеллас Дойчланд Гмбх | Пероральные лекарственные формы бендамустина |
| AU2010338249B2 (en) | 2009-12-28 | 2016-03-31 | Laboratorio Reig Jofre, S.A. | Oral liquid pharmaceutical composition of nifedipine |
| CN102970990A (zh) | 2010-05-03 | 2013-03-13 | 帝国制药美国公司 | 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法 |
| MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
| CN102389401B (zh) * | 2011-11-22 | 2013-05-22 | 陆荣政 | 一种右旋布洛芬颗粒及其制备方法 |
| KR101211902B1 (ko) * | 2012-04-30 | 2012-12-13 | 주식회사 휴온스 | 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물 |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| JP6571657B2 (ja) | 2013-08-27 | 2019-09-04 | ボウドウリス バシリオス | ベンダムスチンの薬学的組成物 |
| ES2759004T3 (es) * | 2014-11-04 | 2020-05-07 | Innopharmax Inc | Administración oral de medicamentos inestables o mal absorbidos |
| US20180243224A1 (en) * | 2015-08-19 | 2018-08-30 | Vivus, Inc. | Pharmaceutical formulations |
| JP6103111B1 (ja) | 2016-05-24 | 2017-03-29 | 三生医薬株式会社 | 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法 |
| JP2020152674A (ja) * | 2019-03-20 | 2020-09-24 | 株式会社リコー | 難水溶性化合物の可溶化物の製造方法 |
| EP3998063A4 (en) * | 2019-07-08 | 2023-03-15 | MORESCO Corporation | COMPOSITIONS FOR PREPARING MICROEMULSION, MICROEMULSION, METHOD FOR PRODUCING COMPOSITION AND MICROEMULSION, AND USE OF MICROEMULSION |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8630273D0 (en) * | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| AU1766592A (en) * | 1991-06-03 | 1993-01-08 | Merck Sharp & Dohme Limited | Pharmaceutical formulations of a benzodiazepine |
| US6054136A (en) * | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US6312704B1 (en) * | 1993-09-30 | 2001-11-06 | Gattefosse, S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| AU692255B2 (en) * | 1995-04-24 | 1998-06-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
| SK53697A3 (en) * | 1995-08-25 | 1997-10-08 | Sangstat Medical Corp | Oral cyclosporin formulations |
| KR970064620A (ko) * | 1996-03-05 | 1997-10-13 | 임성기 | 사이클로스포린-함유 외용약제 조성물 |
| US5993858A (en) * | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| BR9807528A (pt) * | 1997-01-30 | 2000-03-14 | Novartis Ag | Composições farmacêuticas isentas de óleo contendo ciclosporina a |
| HU228855B1 (en) * | 1997-03-12 | 2013-06-28 | Abbott Lab | Hydrophilic binary systems for the administration of cyclosporine |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| JP2002513750A (ja) * | 1998-05-07 | 2002-05-14 | エラン コーポレーシヨン ピーエルシー | 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム |
| ES2215277T3 (es) * | 1998-08-18 | 2004-10-01 | Panacea Biotec Limited | Composicion de ciclosporina que comprende un vehiculo hidrofilo. |
| IL143580A0 (en) * | 1998-12-11 | 2002-04-21 | Pharmasolutions Inc | Pharmaceutical compositions containing lipophilic drugs and methods for the preparation thereof |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6057289A (en) * | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
| US6596306B1 (en) * | 2000-07-07 | 2003-07-22 | David Ho Sue San Ho | Drug delivery system:formulation for fat-soluble drugs |
| DE10133305B4 (de) * | 2001-07-12 | 2004-06-03 | Aquanova German Solubilisate Technologies (Agt) Gmbh | Ubichinon Konzentrat |
| US6960563B2 (en) * | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
| JP2005343799A (ja) * | 2004-05-31 | 2005-12-15 | Nisshin Oillio Group Ltd | 水分散性植物ステロース製剤と油脂含有水分散性植物ステロール製剤 |
| KR100678829B1 (ko) * | 2004-12-06 | 2007-02-05 | 한미약품 주식회사 | 타크로리무스의 경구용 마이크로에멀젼 조성물 |
-
2007
- 2007-11-21 US US11/944,239 patent/US20090130198A1/en not_active Abandoned
-
2008
- 2008-11-21 JP JP2008298513A patent/JP5491724B2/ja active Active
- 2008-11-21 ES ES08020342T patent/ES2396723T3/es active Active
- 2008-11-21 EP EP08020342A patent/EP2062571B8/en active Active
- 2008-11-21 CN CN2008101811022A patent/CN101439015B/zh active Active
-
2014
- 2014-02-28 JP JP2014038075A patent/JP2014098039A/ja active Pending
-
2016
- 2016-03-17 JP JP2016053870A patent/JP2016106152A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009132712A5 (ja) | ||
| Kaur et al. | Developments of Polysorbate (Tween) based microemulsions: Preclinical drug delivery, toxicity and antimicrobial applications | |
| Wadhwa et al. | Emulsion forming drug delivery system for lipophilic drugs | |
| He et al. | Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs | |
| Nardin et al. | Successful development of oral SEDDS: screening of excipients from the industrial point of view | |
| Talegaonkar et al. | Microemulsions: a novel approach to enhanced drug delivery | |
| Negi et al. | Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique | |
| Kaithwas et al. | Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability | |
| Win et al. | In vitro and in vivo studies on vitamin E TPGS-emulsified poly (D, L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation | |
| Rao et al. | Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases | |
| JP2012111763A (ja) | 自然分散性ｎ−ベンゾイルスタウロスポリン組成物 | |
| JP2003530314A5 (ja) | ||
| JP2015504924A5 (ja) | ||
| CA2478424A1 (en) | Self emulsifying drug delivery systems for poorly soluble drugs | |
| Tatham et al. | Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics | |
| KR20140043297A (ko) | 칼라놀라이드, 이의 유도체 및 유사체에 대한 약학 조성물 및 이의 제조 방법 | |
| NO323425B1 (no) | Farmasoytisk preparat omfattende en pyranonforbindelse, og emulsjoner eller kapsler inbefattende preparatet | |
| Wadhwa et al. | Self-emulsifying therapeutic system: a potential approach for delivery of lipophilic drugs | |
| Elnaggar et al. | Sildenafil citrate nanoemulsion vs. self-nanoemulsifying delivery systems: rational development and transdermal permeation | |
| Akhtar et al. | Self-Generating nano-emulsification techniques for alternatively-routed, bioavailability enhanced delivery, especially for anti-cancers, anti-diabetics, and miscellaneous drugs of natural, and synthetic origins | |
| ES2210056T3 (es) | Preconcentrados en microemulsion y microemulsiones que contienen coenzima q10. | |
| RU2013126259A (ru) | Фармацевтическая композиция таксоидов | |
| EP3148645A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| Lenjisa et al. | New hope for eradication of HIV from the body: the role of polymeric nanomedicines in HIV/AIDS pharmacotherapy | |
| Singh | Self-nanoemulsifying drug delivery system: A versatile carrier for lipophilic drugs |